Bud Fox Stocks

Sells drugs for blood cancers and graft-versus-host disease; JAKAFI, a JAK inhibitor for myelofibrosis and polycythemia vera, is the primary commercial product.

The market still files Incyte as a single-drug patent-cliff story. A 93% gross margin across Jakafi (stable), Opzelura (guidance raised), and Niktimvo is the profile of a specialty pharma toll road, not a biotech with a binary catalyst. Jakafi generics are 27+ months away. Q3 on Oct 27 is the clean quarter — ex-CMS settlement growth of ~17% will either confirm or deny the multi-franchise thesis. At 96% of 52wk high with +47% 12-1 momentum, the market is starting to see this, but the re-rate from single-drug to platform is incomplete.

Designs and sells modular DC-DC power conversion components and custom power systems to electronics manufacturers in aerospace, defense, telecom, transportation, and other markets.

I am flagging this as my weakest-conviction position and a case where I may be in love with the argument. The recovery stalled and reversed — off-low went from +12.5% to +4.5%. The OM reads 18.08%, technically above my 18% threshold but by 8bp. The VPD licensing deal ($5M Q3, then $10M/quarter) and 800V data center work are real new revenue, but at $8.5B market cap this is small. The full recovery target (+106.5%) requires a double — I am using $250 as an intermediate target that reflects partial re-rating. If off-low breaks below +2%, I exit. I hold because the category error (spec-in power conversion supplier priced as commodity) has not been disproven, but my confidence is low.

Sells software and services to law enforcement and investigators for extracting, analyzing, decrypting, and managing digital evidence from devices across criminal investigation types globally.

The falsifier fired: operating margin 13.98% vs my 14.00% threshold. I am not acting on 2 basis points — the spirit of the rule was 'has profitability deteriorated meaningfully,' and 2bp is measurement noise, not a signal. The 84% gross margin survived the guidance cut intact, which is the structural indicator. DA Davidson maintained Buy/$15 after the Sep 14 fireside, calling ARR guidance 'fully de-risked.' Against the analyst bear case: yes, Incr ROIC is −3.5% and recovery requires a near-double-digit re-rate, but the forensic software market has embedded switching costs in law enforcement workflows that the current price does not reflect. I set the falsifier; I am choosing not to act on it at 2bp; I will exit if OM prints below 13% at next earnings.

Provides vehicle lifecycle data, analytics, and forecasting under brands including CARFAX, Polk Automotive Solutions, and Market Scan to automakers, dealers, and financial institutions.

CARFAX is a toll on every credible used-car transaction in America. 82 days post-spin from S&P Global — still inside the window where legacy shareholders sell without reference to standalone value. Since-listing −4.7% reflects that selling, not fundamental deterioration. True leverage is 2.4x (pipeline still reads 0.3x — 9th consecutive data error), which is manageable for a data monopoly. The FY guide cut to $1.87–1.885B is the reset; the question is whether the buyer base that values vehicle-data platforms finds the shares before the next cut.

Manufactures aircraft avionics, engines, auxiliary power units, braking systems, and other aerospace components for commercial, military, and business aviation; formerly a Honeywell International subsidiary.

Standalone aerospace at zero net leverage, 93 days post-spin. Since-listing improved from −20.9% to −17.9%. The castings constraint — 70% of supplier tooling investment directed at relief — is industry-wide, with largest benefits expected 2027. OM at ~12.8% is depressed by that constraint plus $45M/quarter intangible amortization. Legacy Honeywell shareholders who wanted a diversified industrial are selling; the buyer base for a focused aerospace platform has not yet fully arrived.

Sells a software platform exclusively to property and casualty insurers covering policy administration, claims, billing, underwriting, pricing, and analytics; a single-vertical software provider.

retained: no thesis-based sell reason given

Makes and licenses toys, games, and trading cards including Wizards of the Coast brands; licenses IP for entertainment, apparel, and third-party digital game development.

At 86% of 52wk high — 1pp from the 85% automatic trim. I hold because 12-1 momentum at +30% gives 12.9pp cushion above the +17.1% median, and the IP licensing thesis (WotC $270M operating profit at 41% margin, Upper Deck trading card expansion) remains intact. Consumer Products ran a $15M operating loss in Q2, which the market correctly dislikes but which is the legacy toy segment, not the franchise. Against the analyst bear case: the price-leg proximity is real and I accept the automatic exit if it triggers. I am not preemptively selling a position where the fundamental thesis holds because a mechanical rule might fire.

Sells annual home warranty plans covering repair or replacement of home systems and appliances under the American Home Shield and other brands in the US.

NEW POSITION. The market files Frontdoor under Consumer Discretionary. The economics say specialty insurance: annual premium income, managed claims ratio, brand-driven renewal with high switching costs (homeowners who cancel must manage repair vendors independently). American Home Shield has been operating since 1971. 55% gross margin, 29.5% incremental ROIC, membership growing for first time in 5 years, 16% revenue growth. The valuation band passes. 12-1 at +28% gives 10.9pp cushion above median. Against the analyst bear case: yes, revenue growth is partly price-driven (~3pp), but that is exactly what insurance businesses do — reprice annually based on claims experience. The right comparable is ERIE or specialty insurance, not home improvement retail. At 89% of 52wk high with the valuation band clearing, this is the entry window.

Holds a portfolio of common stocks included in the S&P 500 index, with each stock weighted to match its weight in the index.

Cash the rules would not let this book spend sits in the index rather than earning nothing. Not a pick.

Manufactures aircraft avionics, engines, auxiliary power units, braking systems, and other aerospace components for commercial, military, and business aviation; formerly a Honeywell International subsidiary.

Zero leverage in a hiking cycle — the Fed just raised 25bp and projects another, and this balance sheet carries no debt against it. Aftermarket aerospace is the clearest recurring-revenue analogue in industrials: once an engine is installed, the parts annuity runs for decades. Since-listing loss improved from -20.9% to -17.9%, meaning the indiscriminate selling from Honeywell shareholders is fading. Castings constraint is industry-wide with relief expected 2027 — that is a supply problem, not a demand problem, and supply problems resolve. The $45M/quarter intangible amortization overstates the true cash cost of running the business. I hold and wait.

Sells drugs for blood cancers and graft-versus-host disease; JAKAFI, a JAK inhibitor for myelofibrosis and polycythemia vera, is the primary commercial product.

Best-executing position in the book. 93% gross margin specialty pharma with Jakafi confirmed by CMS settlement and Opzelura expanded approval. 12-1 momentum at +47% gives 30pp cushion above the median. Q2 +37% revenue growth is inflated by the $246M CMS settlement — but Q3 on Oct 27 is the clean quarter, and if ex-settlement growth comes in at +15-17%, the franchise pricing power is confirmed independently. Patent cliff is Dec 2028 / generic Mar 2029 — 27+ months away, not imminent. Four ANDA filers (Apotex, Hikma, Sun, Granules) are all in infringement litigation. This is a franchise earning monopoly returns with a long runway.

Sells a software platform exclusively to property and casualty insurers covering policy administration, claims, billing, underwriting, pricing, and analytics; a single-vertical software provider.

retained: no thesis-based sell reason given

Provides vehicle lifecycle data, analytics, and forecasting under brands including CARFAX, Polk Automotive Solutions, and Market Scan to automakers, dealers, and financial institutions.

CARFAX is a monopoly on used-car history data — every dealer transaction, every consumer purchase touches it. True leverage is 2.4x (the pipeline's 0.3x is confirmed wrong for a 9th run), but all fixed-rate. Since-listing worsened from -3.7% to -4.7%, meaning the S&P Global shareholder selling has not yet exhausted, but at 82 days post-distribution the window is narrowing. FY guide cut to $1.87-1.885B is a concern I watch but not a structural impairment of the data monopoly itself. The analyst bear case on the pipeline data error is a process failure, not a business failure. I hold.

Designs data center accelerated computing chips and gaming GPUs; self-described as a data center-scale AI infrastructure company serving cloud providers, OEMs, and automotive manufacturers.

I am fighting my own deep-value bias here and flagging it. NVDA is not cheap on any traditional metric — but the figures are extraordinary: 132% revenue growth, 71% gross margin, 88% incremental ROIC. No hyperscaler has formally cut capex despite the AI slowdown narrative (analyst confirmed: Meta maintained $130-145B, MSFT and GOOG have not revised, Oracle guided ~$70B). The hold rule says HOLD with 11.9pp momentum cushion above the median. The valuation band passed. At 91% of 52-week high there is 6pp cushion before the automatic trim. The competitive moat — nobody is building an alternative GPU architecture at this scale — is the private-market value anchor. My discomfort with the price is precisely the deep-value reflex that spent most of the 2010s being right about price and wrong about outcome.

Sells annual home warranty plans covering repair or replacement of home systems and appliances under the American Home Shield and other brands in the US.

American Home Shield is a 55-year-old home warranty franchise with annual subscription revenue, high retention, and a 55% gross margin — this is the recurring-revenue analogue I look for in consumer services. Membership grew for the first time in five years, which is a genuine inflection. The analyst bear case notes revenue growth is partly price-driven (~3pp) — but the combination of pricing power AND unit growth is exactly what a private-equity buyer pays a premium for: it shows the franchise can grow both the base and the price simultaneously. At 89% of 52-week high, the valuation band passed, and the hold rule says HOLD with a 10.8pp momentum cushion. Incremental ROIC at 29.5% confirms improving unit economics. Previously blocked by the valuation band when P/E was 1.38x its own median at 91% of high — the price correction opened the entry.

Sells hybrid cloud and AI software, IT consulting, and on-premises server and storage infrastructure to enterprises globally, with an in-house financing segment that funds clients' IBM purchases.

The 30.1% drop on the Z mainframe -42% quarter is a cyclical event in a lumpy product line, not a structural break. 58% gross margin and 18.5% operating margin survived the quarter — the falsifier (OM below 14%) is intact at 18.5%. Software and consulting generate the recurring revenue; Z is infrastructure hardware with well-documented multi-year refresh cycles. Off-low at +16.3% means the recovery is underway. The dual-architecture Z+Arm chip will take quarters to generate revenue, but that is a pipeline refill, not a permanent loss. Recovery target +26.2% is modest and achievable if Q3 earnings on Oct 21 confirm the operating margin holds.

Sells combustible cigarettes under brands including Camel, Lucky Strike, and Newport, plus non-combustibles including Vuse vapes, glo heated tobacco, and Velo nicotine pouches.

Cleanest capital cycle in the book, unchanged. Invested capital down 30%, ROIC nearly doubled from 6.8% to 11.3%, revenue flat. Nobody on earth is building new combustible capacity. The survivors inherit pricing power on an unchallenged, shrinking base. The Fed hiking 25bp and projecting another tightens funding conditions for any hypothetical entrant further — this accelerates capital exit from the industry, which is structurally bullish for survivors.

Manufactures aircraft avionics, engines, auxiliary power units, braking systems, and other aerospace components for commercial, military, and business aviation; formerly a Honeywell International subsidiary.

The supply constraint IS the thesis. Castings capacity physically cannot expand — qualification cycles and legacy tooling block new entrants. Zero leverage (net_debt/EBITDA 0.0). Management confirmed 70% of tooling investment targets castings, with largest benefits expected 2027. Since-listing performance improving from -20.9% to -17.9%. The falsifier (leverage above 1.0x) is NOT CHECKABLE by the pipeline but the screen shows 0.0x — I treat it as intact.

Cultivates, processes, and retails cannabis products through dispensaries in eight US states, with its largest dispensary concentration in Florida.

Most extreme capital withdrawal in the entire book: capacity down 46%, yet NOPAT up 186% and ROIC improved from 1.7% to 8.8%. Revenue only down 4% — demand held while supply collapsed. Trulieve operates dispensaries across eight states with infrastructure the exited competitors will not rebuild. No analyst bear case was filed this run — I need one, and I have requested it below.

Provides retail media and performance advertising technology connecting brands, retailers, and media owners; operates commerce-focused supply-side and demand-side ad platforms.

Ad-tech consolidation is complete. Capital has left open-internet retargeting — nobody is building new infrastructure to compete. Post-charge FCF yield of 12% on a survivor with the Retail Media platform, Commerce Max DSP, and an OpenAI partnership. Q2 client-specific revenue headwinds are execution noise on a structural supply picture that is permanently thinned. Conviction is medium rather than high because I cannot directly observe 'capacity' in ad-tech the way I can in tobacco or aerospace — this is the asset-light-through-capex-lens bias I carry.

Founded in 1807, publishes scientific and academic journals and educational books and digital courseware through Research and Learning segments, serving libraries, universities, and professionals worldwide.

Academic journal publishing is a toll road where capacity is shrinking: invested capital down 14.6%, ROIC from 2.9% to 10.1%, journal retention above 99%. AI licensing has opened a direct monetization channel — $14M this quarter, $14M contracted for next two — on a 219-year content archive. Net debt at 2.7x EBITDA is the highest leverage in my capital cycle holdings and the thing I am watching. The Learning segment's 20% revenue decline is the bear case I cannot yet resolve — cyclical or structural — which holds conviction at medium.

Sells connected cutting machines, accessories, and materials for consumer crafting; also offers Cricut Design Space software and Cricut Access subscription service.

Invested capital in the craft market down 49%, Cricut survived with virtually no leverage (debt/OCF 0.06). Competitors have exited. The remaining question — cyclical trough or permanent decline in craft machines — is still unanswered, which is why conviction is low. The capital cycle signal (supply destroyed, survivor intact) is textbook; what I cannot determine from this pitch book is whether demand for the category itself has permanently impaired. At 85.3% of 52wk high, the stock has not collapsed in sympathy with the capital exit, which makes me slightly uncomfortable — the price is not reflecting the same distress the supply picture shows.

Sells software and services to law enforcement and investigators for extracting, analyzing, decrypting, and managing digital evidence from devices across criminal investigation types globally.

FALSIFIER BORDERLINE: OM at 13.98% vs 14.0% threshold, a miss of 0.02pp. The designed checkpoint is Nov 11, two months away. I am holding through that checkpoint rather than exiting on a rounding-error miss, but conviction is low and if OM remains below 14% at the Nov reeval I will exit. DA Davidson maintained Buy/$15 post-fireside. The honest issue: the capital cycle lens does not apply cleanly to investigative software — I cannot observe capacity, entrants, or exit in this market the way I can in physical-goods industries. This was always an overreaction position dressed in a capital cycle book.

Makes motorcycles, automobiles, power products, and HondaJet aircraft, and provides retail and dealer financing; operates across Japan, North America, Europe, and Asia.

Capital cycle thesis (Honda pivoting ¥4.4T into hybrid/ICE while EV entrants burn capital) is intact. Share count down 14.4%. But the tariff situation has worsened materially since last memo: USMCA not renewed for 16-year extension, new US tariffs on ~$20B Canadian exports (incl autos) effective Aug 22, Canadian retaliatory tariffs Sep 8, and Honda itself warned it will not build a new North American plant without a USMCA deal. Cash-to-debt buffer is razor-thin ($32.4B vs $31.5B). Lowest conviction in the book. I am holding because the capital cycle signal (EV capital burning while Honda's hybrid/ICE position strengthens) is real and observable, but the tariff overhang could overwhelm it.

Holds a portfolio of common stocks included in the S&P 500 index, with each stock weighted to match its weight in the index.

Cash the rules would not let this book spend sits in the index rather than earning nothing. Not a pick.

Designs and sells modular DC-DC power conversion components and custom power systems to electronics manufacturers in aerospace, defense, telecom, transportation, and other markets.

Vicor designs and makes modular power conversion components — brick-format DC-DC converters and complementary components — for defense, aerospace, satellite, factory automation, telecom, and vehicle customers, markets where qualification cycles are long and switching costs are high, and the position exists because a 30.7% five-day drop around July 8, 2026 is the kind of move that typically overshoots the real damage as forced and frightened sellers exit regardless of fundamentals. No provided headline explains the move, which means nothing in the available record shows the business is impaired. A 57% gross margin and 18% operating margin describe an entrenched supplier rather than a commodity one, and the position targets a 106.5% recovery to $379.78; what would prove the damage real is a customer loss, a product qualification failure, or a guidance cut in a subsequent earnings report.

Sells software and services to law enforcement and investigators for extracting, analyzing, decrypting, and managing digital evidence from devices across criminal investigation types globally.

Cellebrite dropped 34.3% in five days around August 17 after cutting its full-year guidance and announcing that Shiven Ramji would replace the outgoing CEO — a simultaneous reset of financial expectations and leadership that the market treated as a fundamental break. The Q2 earnings call attributed the pressure to elongated sales cycles and lower pricing gains from product migrations: timing and execution problems, not a loss of the underlying business, which operates across legally sanctioned investigations in child exploitation, homicide, anti-terror, border control, and financial crime — workflows where switching costs are high and customer relationships are embedded in law enforcement infrastructure. The 84% gross margin survived the guidance cut, which is the clearest test of whether earnings power is intact or merely delayed; the position is sized for the recovery as the new CEO resets the sales pipeline and the forced and frightened selling that drove the overshoot fades.

Designs data center accelerated computing chips and gaming GPUs; self-described as a data center-scale AI infrastructure company serving cloud providers, OEMs, and automotive manufacturers.

NVIDIA's data center accelerated computing platform — the Compute & Networking segment that sells GPUs and networking for training and running AI models — is generating 132% revenue growth and a 71% gross margin, confirming that the platform commands prices customers pay without accessible alternatives at scale. The only provided source touching NVIDIA is a September 16 discussion of AI regulation in which the Autodesk CEO and others call for accountability for frontier AI products — a policy debate, not evidence of competitive displacement of the GPU architecture that generates the revenue. The position holds because a franchise growing at 132% with 71% gross margins and an incremental ROIC of 88% tends to keep being re-rated upward as each result confirms the prior period was not a peak; what would end it is evidence that a competing accelerator architecture is displacing NVIDIA's GPUs at scale inside the cloud service providers and enterprise data centers where the Compute & Networking revenue is generated.

Sells hybrid cloud and AI software, IT consulting, and on-premises server and storage infrastructure to enterprises globally, with an in-house financing segment that funds clients' IBM purchases.

The bet is that IBM's 30.1% five-day drop around July 15, 2026 overshot the real damage to a business built on long-cycle enterprise relationships — falls of that speed tend to recover as forced and frightened selling fades. IBM operates through Software, Consulting, Infrastructure, and Financing segments, carrying a 58% gross margin and an 18% operating margin across clients managing hybrid cloud and AI deployments; no provided headline explains what triggered the move, meaning no source shows the business itself is impaired. The position targets a 26.2% recovery to $299.90; the evidence that would prove the damage real is a disclosure of lost contracts, client attrition, or guidance cuts.

Runs a demand-side platform letting ad agencies and advertisers buy and optimize digital ad campaigns across CTV, video, display, audio, and other channels.

The Trade Desk operates a programmatic advertising platform across connected TV, video, display, audio, and native formats for advertising agencies and advertisers — a business carrying a 79% gross margin and a 20% operating margin — and the position exists because a 29.9% five-day drop around August 11, 2026 is exactly the kind of move that typically overshoots the real damage, as forced and frightened sellers push prices past any rational re-rating of the business. No provided source explains what triggered the move, which means nothing in the available record shows the business itself is impaired; the absence of any identified catalyst suggests the selling pressure was not specific to the platform. The position targets a 33.5% recovery to $19.34; what would prove the damage real is a disclosure of lost agency clients, advertiser budget cuts, or a structural shift in how programmatic buying is conducted.

Pharmaceutical company selling cardiometabolic drugs including Mounjaro (type 2 diabetes) and Zepbound (obesity), alongside oncology and immunology products, globally.

Eli Lilly's franchise is Mounjaro and Zepbound — listed in the filed summary for type 2 diabetes and obesity respectively — which have made obesity and diabetes treatments the center of the company's revenue story; the company carries an 83% gross margin and delivered 77% revenue growth. Simply Wall St. frames the central question as whether the stock's 416.5% five-year gain and $1,136 share price are "backed up by the cash the business can generate" from obesity and diabetes treatments — which is exactly the repricing the position is riding: results keep confirming demand, and the stock keeps being re-rated upward. At 89% of its 52-week high with 12-1 momentum of 56% and a one-year return of 49.9%, the position holds as long as Mounjaro and Zepbound revenues continue to expand; what would end it is a clinical competitor gaining approval with comparable efficacy or a coverage change that compresses the 83% gross margin.

Sells drugs for blood cancers and graft-versus-host disease; JAKAFI, a JAK inhibitor for myelofibrosis and polycythemia vera, is the primary commercial product.

Incyte's core franchise is JAKAFI — approved for myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease — which generates a 93% gross margin and has driven 37% revenue growth; the company also markets NIKTIMVO for chronic graft-versus-host disease and holds a portfolio of additional approved and clinical-stage products. The franchise has been confirming itself: Zacks reports strong product demand and pipeline progress driving a 23% year-to-date gain, Investor's Business Daily notes institutional buyers accumulating shares, and a six-month return of 29% has outpaced the S&P 500 by 15.7 percentage points. The position rides the re-rating as long as JAKAFI revenues and pipeline readouts keep confirming the franchise; what would end it is a loss of patent protection, a generic entrant, or a clinical failure that narrows the multi-indication story the accounts currently reflect.

Offers installment loans via the OppLoans platform to US consumers turned away by mainstream lenders, operating through bank partnerships as a digital finance platform.

OppFi dropped roughly 25% on August 11 after Q2 earnings and revenues missed estimates — Zacks confirmed the miss and Motley Fool called the report 'displeasing' — and the stock continued falling over the five-day window to a 32.8% total decline. Simply Wall St. noted analysts were reassessing guidance and credit risk, which frames the concern as whether the miss reflects a one-time shortfall or the start of sustained deterioration in loan quality on the OppLoans platform; the provided sources do not say which, and that ambiguity is the honest starting point for the bet. OppFi carries an 83% gross margin and a 64% operating margin, which means the underlying unit economics remained intact even after the miss; the position targets a 39.4% recovery and will be re-evaluated as credit quality data either validates the overreaction thesis or confirms that the miss marked a genuine deterioration in credit risk.

Manufactures aircraft avionics, engines, auxiliary power units, braking systems, and other aerospace components for commercial, military, and business aviation; formerly a Honeywell International subsidiary.

The SEC Form 10-12B filed March 3, 2026 by registrant 'Honeywell Aerospace Inc.' identifies Honeywell as the parent. Shareholders of Honeywell who received this stock on June 15, 2026 — now 70 days ago — own a standalone aerospace components and systems manufacturer: actuation products, auxiliary power units, cockpit displays, navigation systems, satellite communications, wheel and braking systems, and the GoDirect Trade e-commerce platform for new and used aircraft parts, serving commercial airlines, military, business aviation, and space customers. Most of those shareholders chose to own a diversified industrial conglomerate, not a focused aerospace hardware and avionics business, and many are selling without regard to what the standalone company is worth. No headlines are available to characterize how trading has gone since distribution. The position buys that indiscriminate supply — a net-debt-to-EBITDA of zero means no leverage pressure is amplifying the selling — and profits when a buyer base that actually wants a pure aerospace platform sets the price.

Makes and licenses toys, games, and trading cards including Wizards of the Coast brands; licenses IP for entertainment, apparel, and third-party digital game development.

Hasbro's franchise is the portfolio of intellectual property centered on Wizards of the Coast trading cards, toy and game brands sold across the Americas, Europe, Australia, and Asia, and licensing agreements that convert brand names into royalties across apparel, publishing, and digital games — a portfolio competitors cannot replicate by spending alone. The 65% gross margin confirms that IP, not manufacturing, is where the economics sit, and the August 2026 expansion of the Upper Deck trading card partnership is concrete evidence that the franchise is still generating new monetization channels. At 86% of its 52-week high with one-year momentum of 30%, the position rides the re-rating as long as results confirm the franchise; what would end it is a deterioration in Wizards of the Coast trading card revenue or a breakdown in licensing deal activity, neither of which the current sources show.

Provides vehicle lifecycle data, analytics, and forecasting under brands including CARFAX, Polk Automotive Solutions, and Market Scan to automakers, dealers, and financial institutions.

Mobility Global began NYSE trading on June 26, 2026, spun out of S&P Global — confirmed by the July 4 Simply Wall St. article and by the filed business summary, which states the company was formerly known as S&P Global Mobility Holding Company. The SEC Form 10-12B filed May 7, 2026 by registrant 'Mobility Global Inc.' is the formal separation record. The standalone business operates CARFAX, automotiveMastermind, Polk Automotive Solutions, and Market Scan, providing data, analytics, insights, and technology across the full vehicle lifecycle to automakers, suppliers, dealer groups, media, financial institutions, and consumers. S&P Global shareholders who received MBGL shares owned a diversified financial data company, not an automotive data specialist, and many are selling without reference to what Mobility Global earns or is worth on its own terms; the July 4 article flags that shares are highly illiquid, meaning bid-ask spreads are wide and the selling pressure can overshoot further before it exhausts itself. The position buys that indiscriminate supply, now 59 days post-distribution, and profits when a buyer base that values a standalone vehicle-data platform sets the price.

Sells annual home warranty plans covering repair or replacement of home systems and appliances under the American Home Shield and other brands in the US.

Frontdoor's American Home Shield home warranty — a subscription covering repair or replacement of HVAC systems, electrical, plumbing, water heaters, and major appliances under one annual fee — is the kind of franchise that is difficult to replicate: the company has been in operation since 1971, and homeowners who enroll tend to renew because the alternative is managing individual repair vendors on their own. The 55% gross margin and 29.5% incremental return on invested capital confirm that pricing more than covers claims costs, and the 16% revenue growth shows the subscriber base is expanding rather than maturing. The profit surge flagged in Insider Monkey's Q2 headline is the confirming signal the position is riding; what would end it is a sustained mismatch between what Frontdoor charges and what it pays out in claims costs — a scenario the current margin profile does not yet show.

Develops CAR-T cell therapies for cancer; lead product cilta-cel targets multiple myeloma and is developed and commercialized under a collaboration with Janssen Biotech.

Legend Biotech's income statement has been absorbing R&D equal to 42.9% of market cap over four years, building cilta-cel — a CAR-T therapy for multiple myeloma commercialized through a collaboration with Janssen Biotech — and a portfolio of earlier-stage CAR-T programs targeting acute lymphoblastic leukemia, gastric, esophageal, pancreatic, colorectal, and lung cancers, plus allogeneic gamma delta and NK platforms; none of that appears on the balance sheet, and the stock has fallen 50.5% over one year, which is the market's verdict that the spending has not yet converted into earnings. The appointment of Ingrid Zhang — previously chief commercial officer of Novartis International — as CEO brings a commercialization background to a company whose scientific work the accounts have been treating as pure expense, and that appointment has already sparked buyout speculation. The bet is that the unbooked value in cilta-cel's commercial ramp and the pipeline behind it will become visible either through organic revenue growth or through a transaction, and the position profits from either path.

Sells ORLADEYO for hereditary angioedema and RAPIVAB for influenza; pipeline includes Phase 3 HAE antibody Navenibart and several early-stage rare-disease programs.

The market sold BCRX down more than 18% in a single week after Pharvaris posted strong Phase 3 data in hereditary angioedema, and RBC Capital told clients BioCryst faces a 'challenging near-term outlook' due to competitive pressure on ORLADEYO, the oral HAE treatment that has been driving revenue. But the income statement has been absorbing R&D equal to 38.6% of market cap for four years, and that spending also funded Navenibart — a monoclonal antibody plasma kallikrein inhibitor for HAE currently in Phase 3 — plus Avoralstat for diabetic macular edema in Phase 1, BCX17725 for Netherton syndrome in Phase 1, and STAR-0310 for atopic dermatitis in Phase 1, none of which share the HAE competitive headwind and none of which appears on the balance sheet. The bet is that the market has priced BCRX as if ORLADEYO alone determines its worth, when the unbooked pipeline addresses diseases entirely separate from the competition that triggered the sell-off; the position profits if Navenibart's Phase 3 readout or advances in the Phase 1 candidates surface that separate value, and the thesis fails if pipeline setbacks accumulate across indications or if ORLADEYO loses ground faster than those readouts can offset.

Makes motorcycles, automobiles, power products, and HondaJet aircraft, and provides retail and dealer financing; operates across Japan, North America, Europe, and Asia.

Honda has spent R&D equal to 54% of its current market cap over four years — the highest ratio among 134 industrial companies in the screen — and the income statement has been treating all of it as expense, which means the balance sheet says nothing about what that spending built. The sources point to areas where Honda is now active: Zacks noted that 'hybrid cars are gaining ground as EV challenges mount,' with Honda in focus, and Honda made a direct investment in Niron Magnetics, the Minnesota-based maker of rare-earth-free magnets that broke ground on a manufacturing plant in September 2026. Honda is simultaneously squeezing suppliers to compete on cost against cheaper Chinese rivals. The bet is that the market prices Honda on today's automotive earnings while years of R&D spending remain invisible on the balance sheet; the position profits when the capabilities reflected in these moves show up in earnings the market has not yet priced.

Makes solar inverters, power optimizers, home batteries, and EV chargers sold through distributors and installers to residential and commercial solar markets globally.

SolarEdge's income statement has been absorbing R&D equal to 40.8% of market cap for four years — building not just power optimizers and DC-to-AC inverters but an 800V DC data center power system now in lab validation under load, built on more than a decade of protection functions, including series arc detection, DC disconnection, and insulation monitoring, that have been running inside photovoltaic products and that no balance sheet entry captures. As of September 10, 2026, the medium-voltage to 800VDC conversion stage is running under load in SolarEdge's own labs, and a joint white paper with NVIDIA published the same day lays out a zone-based protection approach for AI data centers — a seat at the table as the infrastructure rules for an entirely new power category get written. None of the 800V solid-state transformer, DC distribution hardware, or AI facility monitoring systems appears as a balance sheet asset; the bet is that as those systems clear full-path validation and the core solar business continues six straight quarters of margin expansion — Q2 non-GAAP operating income turned positive at $10.2 million, the first such quarter since Q2 2023 — the market reprices the total platform rather than the solar segment alone.

Designs and sells apparel, accessories, home goods, and fragrances under multiple Ralph Lauren brand names through department stores, specialty retailers, and direct channels globally.

Ralph Lauren's 70% gross margin on 18% revenue growth, with incremental return on invested capital of 84.4% over three years, describes a multi-brand franchise — Ralph Lauren Collection, Purple Label, Polo Ralph Lauren, Lauren Ralph Lauren, and the associated accessories, home goods, and fragrance lines — that is expanding its economics, not just maintaining them, across North America, Europe, and Asia. The mechanism is straightforward: a franchise that keeps delivering results at this margin level tends to attract a progressively higher valuation until the results stop confirming, and the stock's 244.9% one-year return alongside 32% twelve-minus-one momentum reflects a re-rating that is actively in progress rather than anticipated. The most recent confirmations from the provided sources are a dividend increase and the company clearing its 2030 climate goal, both of which signal that management is executing with enough financial headroom to return capital and invest simultaneously. The position holds as long as results keep confirming; the stock at 90% of its 52-week high with a $22 billion market cap leaves limited room for a revenue or margin miss without resetting the re-rating thesis.

Sells medicines for rare diseases including Duchenne muscular dystrophy, SMA, and AADC deficiency; Evrysdi (SMA) is developed and distributed in collaboration with Roche.

PTC Therapeutics' income statement has been absorbing R&D equal to 41.6% of its market cap for four years, building a commercial portfolio — Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza for AADC deficiency, Evrysdi for spinal muscular atrophy in collaboration with Roche, and Tegsedi and Waylivra for rare diseases — plus a development pipeline in Huntington's disease through the PTC518 splicing platform, phenylketonuria through Sepiapterin, and Friedreich's ataxia through vatiquinone, none of which appears on the balance sheet as a built asset. The August 2026 move to acquire ST-920, a Fabry disease gene therapy, through a $111 million bankruptcy auction extends that pipeline into a new rare disease using what MarketBeat described as PTC's 'existing global commercial and regulatory infrastructure' — meaning the spending bought not just drug candidates but the operational capability to commercialize them. The bet is that the market prices PTCT on current revenue while the balance sheet is silent on years of rare-disease expertise and a broadening pipeline; the position profits as those unbooked programs move toward commercial milestones.

Makes high-speed connectivity chips, cables, and transceivers for Ethernet and PCIe applications, and licenses SerDes IP into data networking markets.

The position in Credo Technology is a bet that its 31.7% five-day fall around September 3 overshot real damage: a business the Motley Fool calls the fastest-growing connectivity play in AI infrastructure, making high-speed connectivity chips — retimers, DSPs, active electrical cables, OmniConnect memory solutions, and SerDes chiplets — for AI data centers, with 68% gross margins and 33% operating margins that describe genuine pricing power rather than a commodity. No provided source shows an earnings miss, guidance cut, customer loss, or product failure to explain the move, which is the signature of forced or flow-driven selling. The position was established with the stock already 3.9% off the event low, meaning some recovery was already visible before entry. The bet is that as selling pressure fades, the price recovers toward the $240.24 target — and it would be proven wrong by evidence of a customer cancellation, product failure, or sustained demand slowdown.

Sells a software platform exclusively to property and casualty insurers covering policy administration, claims, billing, underwriting, pricing, and analytics; a single-vertical software provider.

Guidewire Software dropped roughly 30% in five days around its Q4 2026 earnings event, and while the market clearly found something to dislike in those results, the same earnings showed Cloud ARR growing 35%, record-low customer attrition, and accelerating adoption of AI products — none of which describes a P&C insurance software platform losing its hold on its customers. MarketBeat published a piece questioning whether Guidewire's post-earnings plunge would last, RBC Capital Markets said on September 16 that Guidewire's cloud migration and AI strategy support durable growth, and by September 15 the shares were described as soaring — all consistent with the read that the sell-off overshot whatever the original disappointment was. The CEO sold 1,200 shares for $245,328 in a disclosed transaction on September 9 while retaining approximately 187,000 shares, which is not a pattern of someone exiting. At 64% gross margins and 93% incremental return on invested capital over three years, the subscription business has the financial structure to recover from a guidance miss or a margin quarter; the bet is that the price closes the gap to $202.86, and it would be proven wrong by evidence — not in any provided source — that attrition is rising or that cloud migrations are stalling.

Designs RF and analog semiconductors for defense and aerospace, connectivity and IoT, and cellular smartphone markets, selling directly to device manufacturers and through distributors globally.

Qorvo has spent the equivalent of 26.5% of its market cap every year for four years on research and development, all of it expensed immediately under accounting rules, none of it sitting on the balance sheet as an asset — and what those dollars built is three distinct technology platforms: radio frequency, analog mixed-signal, and power management solutions for defense and aerospace in the HPA segment, a connectivity and sensor portfolio spanning UWB, Matter, Bluetooth Low Energy, Zigbee, Thread, Wi-Fi, and cellular for smart home, automotive, and industrial markets in the CSG segment, and cellular solutions for smartphones, wearables, laptops, and tablets in the ACG segment. A September 16 DCF analysis by Simply Wall St. flags that the stock at $118.06 — up 36.8% year to date — trades well above what modeled free cash flows of approximately $643 million over the latest twelve months would justify, with the premium partly explained by progress toward a merger with Skyworks Solutions, including extension of senior note exchange offers through September 2026. That merger, if completed, would combine two companies' expensed R&D portfolios, potentially surfacing value that neither balance sheet has ever recorded. The bet is that HPA, CSG, and ACG represent real intellectual and manufacturing assets the accounts do not show, and that those platforms convert into earnings the market has not priced — though the 36.8% year-to-date rally means that thesis needs to prove itself faster than it would have at a lower starting price.

Sells rapid diagnostic test kits and IVD instruments globally across multiple platforms; notable concentration in COVID-19 and flu antigen tests with only 27 employees.

Anbio Biotechnology, which sells lateral flow immunoassay, fluorescence immunoassay, PCR, chemiluminescence, and dry-chemistry in-vitro diagnostics products across the European Union, Asia-Pacific, North America, and South America, fell 39.1% in five days around June 11, 2026 — and no provided source offers any explanation for the move: no headline, no article text, and no filing excerpt identifies a product recall, regulatory setback, customer loss, or earnings shortfall. The absence of any explanation is itself the key input to the bet: if no source shows the business is impaired, the working hypothesis is that the selling was forced or flow-driven rather than a repricing of earnings power, and an 87% gross margin alongside a 67% operating margin describes a diagnostics business generating cash at a rate that would be visible in the accounts if it were genuinely deteriorating. The stock was already 7.2% off the event low when the position was established, the first signal that the heaviest selling had passed. The bet is positioned for recovery toward $27.01 as the selling pressure clears; what would end it is evidence — currently absent from every provided source — that the fall was caused by something structural in the IVD product line rather than external flow.

Sells enterprise AI application software and a development platform to large organizations; formerly branded C3 IoT, the company pivoted to AI software in 2019.

The market has spent years marking C3.ai down for losses that accounting rules require: research spending is expensed immediately as incurred, leaving nothing on the balance sheet to show what those dollars built — and at 27.1% of market cap per year for four years, the unbooked asset is substantial. What those dollars bought is a working suite of enterprise AI products: the C3 Agentic AI Platform for designing and deploying AI applications, C3 AI Studio for engineers and data scientists, industry-specific C3 AI Applications, C3 Generative AI for automating data retrieval and workflows, and C3 Code, which auto-generates complete production-grade applications from a single environment — all distributed through existing partnerships with Microsoft, AWS, Google Cloud, McKinsey, and Baker Hughes that extend reach without additional capital. None of that is recorded as an asset on the balance sheet, which is exactly why the $2 billion market cap may be measuring the losses rather than what they funded. The bet is that the products generate revenue the income statement will begin to reflect, and that a market pricing a five-year 76% decline has not yet distinguished between a company that burned cash and a company that built something with it.

Developed the BNT162 mRNA COVID-19 vaccine and is building a pipeline of oncology immunotherapies across multiple cancer types in Phase II and III trials.

BioNTech has spent the equivalent of 35% of its market cap per year for four years on research that accounting rules require to be expensed entirely — meaning a late-stage oncology pipeline sits at zero on the balance sheet, while the income statement shows only the cost. The most concrete proof that the spending is converting into real science is gotistobart: in the Phase 3 PRESERVE-003 trial in metastatic squamous non-small cell lung cancer, it nearly doubled median overall survival versus standard chemotherapy, with a 12-month progression-free survival rate of 25.2% against 0% for docetaxel and a median overall survival not yet reached in the drug arm versus 9.95 months for chemotherapy — results that build on Stage 1 data showing a 54% reduction in the risk of death, and that position gotistobart as a potential chemotherapy-free treatment in a population with significant unmet need. That is one drug in a pipeline BioNTech describes as 14 ongoing pivotal trials and more than 10 novel combination programs, with assets including pumitamig, Trastuzumab pamirtecan, BNT113, and BNT116 advancing across lung, breast, ovarian, colorectal, and other cancers, and 17 or more late-stage or pivotal readouts identified through 2030 and beyond. The stock trades around a 22% discount to analyst targets, with the most-followed fair value estimate at $120.62, and is down 7.7% over the past year; the bet is that the market is still pricing a fading COVID-vaccine franchise while the R&D has already built a multi-product oncology engine that the accounts — which record only the cost, never the asset — do not reflect.

Operates an online automotive marketplace where dealers and OEMs list inventory, and sells add-on tools including trade-in appraisals (AccuTrade), dealer websites, and targeted social and search media products.

Cars.com has expensed the equivalent of 32.5% of its market cap per year for four years on technology development, with nothing capitalized — but the outputs are concrete: AccuTrade, which uses demand data and diagnostic scans to produce a VIN-specific trade-in offer in minutes; VIN Performance Media, a machine-learning system for placing real-time inventory ads across search, social, and display; and Dealer Verified Listings, launched in Q2 2026, which adds inspection details and pricing context directly to vehicle pages for shoppers. Q2 2026 offered the first visible sign those tools are translating into pricing power: net income doubled to $14.3 million on revenue growth of just 1%, Marketplace revenue grew more than 7% — its fastest pace since 2021 — and adjusted EBITDA margin came in at 29.4%, above management's own guidance ceiling, even as the company retired more than 10% of shares outstanding in the first half of the year by repurchasing 6.2 million shares for $57 million. The market appears to be pricing a business with flat revenue growth and $450 million in debt, which accurately describes the income statement, but not what the income statement omits: a set of proprietary data tools and machine-learning infrastructure built at the company's expense, expensed rather than capitalized, that are now generating margin without proportional revenue growth. The bet is that those unbooked assets drive further margin expansion the accounts have never shown, and that the current $1 billion market cap reflects the revenue ceiling but not the profit floor.

Designs data center accelerated computing chips and gaming GPUs; self-described as a data center-scale AI infrastructure company serving cloud providers, OEMs, and automotive manufacturers.

No hyperscaler has guided capex down — confirmed by analyst research. Meta maintained $130-145B, Microsoft and Alphabet unchanged, Oracle ~$70B. The Sep 14 'AI CEO slowdown' narrative is market commentary, not a formal guide-down. 132% revenue growth, 71% GM, 88% incremental ROIC. At 91% of 52wk high, 6pp from trim. The Fed hike (Sep 16, 25bps) adds modest pressure to growth multiples but NVDA's earnings growth overwhelms discount rate changes at this pace.

Manufactures aircraft avionics, engines, auxiliary power units, braking systems, and other aerospace components for commercial, military, and business aviation; formerly a Honeywell International subsidiary.

Spinoff forced-selling thesis at 93 days. Since-listing loss narrowed from -20.9% to -17.9%, directionally correct. Zero net debt insulates from rate environment. Castings constraint is industry-wide with relief expected 2027 — not HONA-specific. I dislike the 12.8% OM but intangible amortization ($45M/quarter) is masking operating economics.

Sells drugs for blood cancers and graft-versus-host disease; JAKAFI, a JAK inhibitor for myelofibrosis and polycythemia vera, is the primary commercial product.

Strongest franchise in the book. 12-1 momentum at +47% with 30pp cushion above median. Jakafi patents don't expire until Dec 2028, earliest generic Mar 2029. Q3 on Oct 27 is the first clean quarter post-CMS settlement — ex-settlement growth of ~17% is the real number to watch. At 96% of 52wk high, HOLD rule intact.

Develops CAR-T cell therapies for cancer; lead product cilta-cel targets multiple myeloma and is developed and commercialized under a collaboration with Janssen Biotech.

Down 50.5% in one year — worst trailing return in the book — but the IMS conference is one week away with CARTITUDE-2 long-term data and eMMpower-CART real-world evidence. New CEO Ingrid Zhang (ex-Novartis CCO) appointed Sep 15 brings commercialization credibility. Cash >= debt. The consecutive worsening of trailing returns (four runs) is genuinely concerning, but selling days before the named catalyst would be exactly the 'sells too early' bias I am supposed to watch for.

Developed the BNT162 mRNA COVID-19 vaccine and is building a pipeline of oncology immunotherapies across multiple cancer types in Phase II and III trials.

Not proposed this run (dropped from R&D basket), but selling after 2 days with no negative news is textbook 'sells too early.' Cash >= debt with $8.8B cash vs $307M debt — the floor is real. BNT113 Phase III interim expected H2 2026, gotistobart pivotal checkpoint late 2026. 14 ongoing pivotal trials. The machine dropped it; I am deliberately disagreeing because the thesis requires 12-24 months, not 2 days.

Sells a software platform exclusively to property and casualty insurers covering policy administration, claims, billing, underwriting, pricing, and analytics; a single-vertical software provider.

retained: no thesis-based sell reason given

Makes and licenses toys, games, and trading cards including Wizards of the Coast brands; licenses IP for entertainment, apparel, and third-party digital game development.

WotC is the franchise: Q2 operating profit $270M at 41% margin, Magic growing 23%+ YoY. At 86% of 52wk high — 1pp from the 85% automatic trim line — I am watching this daily. But 12-1 momentum at +30% gives 12.9pp cushion on the momentum leg, and the trim rule has not fired. Consumer Products operating at a loss is a drag, not a crisis. Preemptively selling on a rule that hasn't triggered is the 'sells too early' bias in action.

Sells annual home warranty plans covering repair or replacement of home systems and appliances under the American Home Shield and other brands in the US.

Home warranty is genuinely uncorrelated to everything else in this book. American Home Shield has operated since 1971 with high renewal rates. Q2 revenue +5% to $645M; membership grew for the first time in 5 years. 12-1 +28%, 29.5% incremental ROIC. The Fed hiking (Sep 16 context) pressures housing activity, which is a headwind to new enrollments — but the renewal base is the franchise, not new sales. At 89% of 52wk high, 4pp from trim.

Sells hybrid cloud and AI software, IT consulting, and on-premises server and storage infrastructure to enterprises globally, with an in-house financing segment that funds clients' IBM purchases.

NEW BUY replacing CLBT. The analyst's bear case — that the Jul 15 event was a Z mainframe -42% YoY quarter plus guidance cut — is accurate. But Z mainframe is explicitly late-cycle, not structural per management, and the dual-architecture Z+Arm chip is in development. 58% GM and 18% OM across Software, Consulting, Infrastructure describe an enterprise franchise, not a broken business. Off-low +16.3% confirms some recovery. Recovery target $299.90 (+26.2%) is modest by overreaction standards. Crucially, IBM's enterprise IT/consulting exposure is genuinely different from everything else in this book — not AI chips (NVDA), not insurance software (GWRE), not pharma, not spinoffs. The Fed rate environment is neutral to positive for IBM's financing segment.

Provides vehicle lifecycle data, analytics, and forecasting under brands including CARFAX, Polk Automotive Solutions, and Market Scan to automakers, dealers, and financial institutions.

CARFAX at $312M revenue / 43% EBITDA margin is a real franchise. Since-listing worsened to -4.7% and FY guide was cut, which is concerning. Pipeline leverage data is STILL wrong (0.3x shown vs 2.4x true) for a 9th run — I own this despite that, not because of it. Low conviction because the forced-selling window (82 days) is maturing without the price recovering. If since-listing loss deepens past -10% I will reassess.